A source from the European Medicines Agency (EMA) confirmed “a link” between the AstraZeneca vaccine and cases of thrombosis recorded in people who received the drug, said this Tuesday (06/04) in an interview with the Italian newspaper The messenger“Now we can say, it is clear that there is a link with the vaccine, which causes this reaction. But we still don’t know why (…) In summary, in the next few hours we will declare that there is a link, but we still have to understand why it happens, “said Marco Cavaleri, director of strategy EMA vaccines.The European agency must give its opinion officially on the subject, said Cavaleri.
“We are trying to have an accurate picture of what is happening, to define the syndrome due to the vaccine (…) Among the vaccinated people, a number of cases of thrombosis higher among young people than we expected. We will have to affirm this “, he explained.
Suspicions about possible effects have been detected for several weeks collateral serious, although rare, among people vaccinated with the AstraZeneca drug. These would be cases of atypical thrombosis, including some that caused death.
In the UK there were 30 cases and seven deaths of a total of 18.1 million doses administered up to March 24.
For EMA “there was no causal link with the vaccine“, said the executive director of the agency, Emer Cooke, a few days ago.
For the European agency according to the knowledge scientists current, “there is no evidence to support the restriction of the use of this vaccine in any population”.
For Paul Hunter, a specialist in medical microbiology at the University of East Anglia, interviewed by AFP, “the evidence points more to the Oxford-AstraZeneca vaccine as the cause”.
As a precaution, vrios passes determined the application of this vaccine to some age groups, such as France, Germany and Canada.
For AstraZeneca, the benefits of the vaccine in preventing covid-19 outweigh the risks of side effects. O laboratory Anglo-Swedish said on Saturday that “patient safety” is his “top priority”.
Get the latest news delivered to your inbox
Follow us on social media networks